文献速递姑息放疗与转移瘤泌尿生殖与妇科肿瘤放疗

因前列腺癌死亡患者姑息性骨转移放疗的人群研究

A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer.
PubMed 文献 · Pract Radiat Oncol · 2019-01-11

该研究基于不列颠哥伦比亚省人群注册数据,分析2003至2015年间因前列腺癌死亡的5701例患者的姑息性骨转移放疗使用情况。总体使用率为38.6%且呈上升趋势,51%接受≥2疗程,5.4%在生命最后4周内接受放疗且其中60%采用多分次方案。农村地区转诊率和使用率较低,首次放疗后中位生存从8.2个月(2003-2004)增至9.4个月(2013-2014,P=.04)。

要点

  • 因前列腺癌死亡患者中姑息性骨转移放疗总体使用率为38.6%,51%接受≥2疗程。
  • 5.4%在生命最后4周内接受放疗,其中60%采用多分次方案。
  • 农村地区转诊率和使用率较低,首次放疗后中位生存从8.2个月增至9.4个月(P=.04)。

核心结论

  • 姑息性骨转移放疗仅用于少数因前列腺癌死亡的患者,多数在首次疗程后一年内死亡。
  • 生命最后4周内多分次放疗常见,首次放疗后生存随时间仅轻微增加。
  • 农村与非农村地区转诊率和使用率存在差异,作者认为需要进一步研究其他障碍并确保公平获得放疗。

研究设计与样本

  • 基于人群的省级注册研究,纳入2003至2015年间诊断前列腺癌并死亡的患者(n=23,260),分析患者与治疗特征。
  • 从首次和末次姑息性骨转移放疗计算生存,按年份和地点计算使用率。

主要发现

  • 共有5701例患者死于前列腺癌,诊断后中位生存5.2年。
  • 总体姑息性骨转移放疗使用率为38.6%,随时间呈上升趋势。
  • 51%的患者接受≥2疗程姑息性骨转移放疗。
  • 因前列腺癌死亡患者中5.4%在生命最后4周内接受姑息性骨转移放疗,其中60%接受多分次方案。
  • 首次姑息性骨转移放疗后中位生存从2003至2004年的8.2个月增至2013至2014年的9.4个月(P=.04)。

关键数值与推荐

  • 姑息性骨转移放疗使用率38.6%,51%接受≥2疗程。
  • 生命最后4周内接受放疗者占5.4%,其中60%为多分次。
  • 首次放疗后中位生存8.2个月(2003-2004)vs 9.4个月(2013-2014),P=.04。
  • 农村地区转诊率和使用率较低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Increasing the survival of patients with metastatic prostate cancer (PCa) may affect the demand for palliative radiation to bone (PRTB). Our aim was to characterize the use of PRTB in patients who died of PCa in British Columbia between 2003 and 2015. METHODS AND MATERIALS: All patients with a diagnosis of PCa who died during the study period (n = 23,260) were identified from a population-based provincial registry. Patient and treatment characteristics were analyzed. PRTB utilization rate was calculated by year and location. Survival was calculated from the first and the last course of PRTB. RESULTS: A total of 5701 patients died of PCa, with a median survival from diagnosis of 5.2 years. The overall PRTB utilization rate was 38.6%, with an increasing trend over time. Multiple courses of PRTB were frequent, with 51% of patients receiving ≥2 courses of PRTB. Of the patients who died of PCa (15.2% of the PRTB cohort), 5.4% received PRTB within the last 4 weeks of life, 60% of whom received multiple fractions. Rural areas had a lower referral rate and lower use of PRTB. Patients with longer survival tended to receive multiple courses of treatment. The median survival after the first course of PRTB increased from 8.2 months in 2003 to 2004 to 9.4 months in 2013 to 2014 (P = .04). CONCLUSIONS: PRTB is only used in a minority of patients dying of PCa. The majority who die of PCa after PRTB do so within a year of their first course. The use of multifractionation was common in the last 4 weeks of life. Survival after first PRTB increased minimally over time, and additional research is required to identify its association with recent changes in practice. The referral rate and PRTB utilization rate differ between rural and nonrural locations, underlying the importance of accessibility and referral for utilization of PRTB. Investigating other barriers and ensuring equitable access to radiation are needed.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Cho CJ, Sunderland K, Pickles T, et al. A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer. Pract Radiat Oncol. 2019. PMID: 30641243. doi:10.1016/j.prro.2019.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。